Novel Endothelial Molecular TargetsSupervisors
The CD146 group is interested in the role of this molecule and its soluble form in various pathologies related to inflammation and angiogenesis.
In this framework, we are working on the role of soluble CD146 (CD146s) as a potential biomarker in scleroderma. On the other hand, we have identified a role of CD146s in placental vascular development and trophoblastic invasion, suggesting its involvement in embryonic implantation. These results led us to propose CD146s as a biomarker in in vitro fertilization, allowing the selection of the embryo to be implanted.
We have also generated different models of transgenic mice in order to study the role of CD146 in atherosclerosis. We were able to show that CD146 is a major protein in the prevention of atherosclerosis. Our goal is now to make it a therapeutic molecule by targeting it in a targeted manner in atheromatous plaque.
Another part of our work is to study the role of this molecule in the development of fibrosis, in particular cardiac and renal fibrosis. To do this, we use different models of myocardial infarction or chronic renal failure as well as cultured cardiac and renal endothelial cell models.
Finally, we are also studying the role of CD146/CD146s in oncology. We have been able to show that this molecule is involved in angiogenesis and tumor growth but also in metastatic dissemination. To combat these effects, we have generated various monoclonal antibodies for therapeutic purposes, some of which are now humanized and tested in preclinical models of glioblastoma or pancreatic cancer.
All of this work has led to the production of scientific articles but also patents which then provide opportunities for Research and Development contracts with the pharmaceutical industry.